Clinical Scorecard: Fibromyalgia Drugs Tested for Value
At a Glance
| Category | Detail |
|---|---|
| Condition | Fibromyalgia |
| Key Mechanisms | Cost-effectiveness analysis of fibromyalgia treatments |
| Target Population | Adults aged 18 years or older with moderate to severe fibromyalgia |
| Care Setting | US healthcare payer perspective |
Key Highlights
- Duloxetine 120 mg produced more QALYs than amitriptyline (10.40 vs 9.99)
- Incremental cost-effectiveness ratio of duloxetine 120 mg is $1,536 per QALY
- Duloxetine 120 mg is cost-saving relative to amitriptyline when indirect costs are included
- Pregabalin 450 mg generated fewer QALYs compared to duloxetine 120 mg despite higher costs
- Sensitivity analyses indicate duloxetine 120 mg has the highest probability of being cost-effective
Guideline-Based Recommendations
Diagnosis
- Assess fibromyalgia severity and impact on quality of life
Management
- Consider duloxetine 120 mg as a first-line treatment option
Monitoring & Follow-up
- Evaluate patient response and adjust treatment as necessary
Risks
- Be aware of potential economic dominance of other treatments
Patient & Prescribing Data
Predominantly women with a mean age of 48.4 years
Duloxetine 120 mg offers the greatest economic value for fibromyalgia treatment
Clinical Best Practices
- Incorporate societal costs in treatment decisions
- Utilize decision analytical models for treatment evaluation
- Monitor real-world treatment patterns and adjust models accordingly
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
